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Traditional  uses  of  Achillea  millefolium  L. (Asteraceae)  include  the  treatment  of cardiovascular  diseases.  In
the  present  study,  we  used  anesthetized  rats  to  assess  the  hypotensive  effect  of  a hydroethanolic  extract
(HEAM),  and  its dichloromethane  (DCM),  ethyl  acetate  (EA),  butanolic  (BT),  and  dichloromethane-2
(DCM-2)  fractions,  besides  the ﬂavonoid  artemetin,  isolated  from  A.  millefolium.  The  oral  administra-
tion  of  HEAM  (100–300  mg/kg),  DCM  (20 mg/kg),  DCM-2  (10–30  mg/kg),  but not EA  (10  mg/kg)  and  BT
(50  mg/kg)  fractions  signiﬁcantly  reduced  the  mean  arterial  pressure  (MAP)  of normotensive  rats.  The
phytochemical  analysis  by NMR 1H  of  DCM  and  DCM-2  fractions  revealed  high  amounts  of  artemetin,
that  was  isolated  and  administered  by  either  oral  (1.5  mg/kg)  or intravenous  (0.15–1.5  mg/kg)  routes  in
rats. This  ﬂavonoid  was  able  to  dose-dependently  reduce  the MAP,  up  to 11.47  ±  1.5 mm Hg (1.5 mg/kg,
i.v.).  To  investigate  if artemetin-induced  hypotension  was  related  to angiotensin-converting  enzyme
inhibition,  we evaluated  the  inﬂuence  of this  ﬂavonoid  on the vascular  effects  of both  angiotensin  I
and  bradykinin.  Intravenous  injection  of  artemetin  (0.75  mg/kg)  signiﬁcantly  reduced  the  hyperten-
sive  response  to angiotensin  I  while  increased  the average  length  of  bradykinin-induced  hypotension.
Artemetin  (1.5  mg/kg,  p.o.)  was also  able  to  reduce  plasma  (about  37%)  and  vascular  (up to  63%)  ACE
activity  in  vitro,  compared  to  control  group.  On the  other  hand,  artemetin  did not change  angiotensin
II-induced  hypertension.  Our  study  is the  ﬁrst  showing  the  hypotensive  effects  induced  by  the  extract
and fractions  obtained  from  A. millefollium.  In addition,  our  results  disclosed  that  this  effect  may  be, at
least  in  part,  associated  with  high  levels  of artemetin  and  its  ability  to  decrease  angiotensin  II  generation
.in  vivo,  by ACE  inhibition
. Introduction
Achillea millefolium L. (Asteraceae) is a perennial herb that has
een extensively used in folk medicine around the world (Chandler
t al., 1982; Wichtl and Bisset, 1989). In Brazil, it is popularly known
s “mil-folhas”, “novalgina”, “erva-de-carpinteiro”, “aquileia”. This
lant is traditionally indicated against gastrointestinal disorders
Benedek and Kopp, 2007; Nemeth and Bernath, 2008), liver and
all-bladder conditions (Haggag et al., 1975; Miraldi et al., 2001),
enstrual irregularities (Newall et al., 1996), fever (Blumenthal
∗ Corresponding author at: Faculty of Medical Sciences, Federal University of
rande Dourados – Rodovia Dourados – Itahum, Km 12, Caixa Postal 533, Dourados,
9.804-970 MS,  Brazil. Tel.: +55 67 3410 2321; fax: +55 41 3410 2320.
E-mail address: candida2005@gmail.com (C.A.L. Kassuya).
944-7113 © 2011 Elsevier GmbH. 
oi:10.1016/j.phymed.2011.02.005
Open access under the Elsevier OA license.© 2011 Elsevier GmbH. 
et al., 2000), wound healing (Aljancic et al., 1999), and cardiovascu-
lar diseases (Font Quer, 1988; Martínez, 1996). Several traditional
uses have been investigated in experimental studies, including
anti-inﬂammatory (Benedek et al., 2007), analgesic (Pires et al.,
2009), anti-ulcer (Cavalcanti et al., 2006), and hepatoprotective
(Yaeesh et al., 2006). Although preparations obtained from this
plant have been widely used as antihypertensive and diuretic by
human subjects, there are no scientiﬁc data supporting none of
these applications.
Phytochemical screenings revealed that chemical constituents
of A. millefolium L. presents several secondary metabolites, includ-
Open access under the Elsevier OA license.ing essential oil (cineol, borneol, pinenes, camphor, menthol,
eugenol, azulen, and chamazulene; Lorenzi and Matos, 2002;
Panizza, 1997), sesquiterpenes (paulitin, isopaulitin, psilostachyin
C, desacetylmatricarin, and sistenin; Csupor-Lofﬂer et al., 2009;
Glasl et al., 2002), the alkaloid achilleine (Miller and Chow,
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954), steroids (-sitosterol, stigmasterol, cholesterol, campes-
erol; Chandler et al., 1982), triterpenes (-amyrin, -amyrin,
araxasterol, pseudotaraxasterol; Chandler et al., 1982), and
avonoids (such as centaureidin, casticin, apigenin, luteolin, rutin,
uercetin, acacetin, isorhamnetin, and artemetin; Csupor-Lofﬂer
t al., 2009; Guédon et al., 1993; Teske and Trentini, 1997). A num-
er of these substances had beneﬁcial effects evidenced in several
athological conditions.
Taking into account the lack of studies regarding the car-
iovascular effects of A. millefolium,  we have investigated if the
ydroethanolic extract obtained from its aerial parts, as well as
emi-puriﬁed fractions, would be able to induce any changes in
lood pressure of anesthetized rats. Using a bio-guided approach
e have characterized that the most active fraction was rich
n artemetin (5-hydroxy-3,6,7,3′,4′-pentamethoxyﬂavone). This
avonoid has been scarcely studied regarding its biological effects,
ut antioxidant (Dugas et al., 2000) and, anti-inﬂammatory (Sertie
t al., 1990) properties, as well as its ability to inhibit the cell cycle
Li et al., 2005), and the enzyme lipoxygenase (Choudhary et al.,
009) have been previously established. Nevertheless, there are no
tudies investigating the effects of artemetin in the cardiovascu-
ar system. As our results will show, artemetin seems responsible,
t least in part, for the anti-hypertensive action attributed to A.
illefolium, an effect mediated by angiotensin-converting enzyme
nhibition.
. Material and methods
.1. Drugs and reagents
Angiotensin I, angiotensin II, bradykinin, captopril and losartan
ere all purchased from Sigma (St. Louis, MO,  USA). Bradykinin,
nd angiotensins I and II (stock solution) were dissolved in HCl
0.1 N). All other drugs were freshly prepared in saline solution
0.9%).
.2. Animals
Male Wistar rats (220–280 g), supplied by Universidade Fed-
ral do Paraná (UFPR, Curitiba, PR, Brazil), were housed in a
emperature- and light-controlled room (22 ± 2 ◦C; 12 h light/dark
ycle), and acclimatized in our laboratory for a period of at least
2 h before any experiment, with free access to water and food. All
rocedures were approved by the Institutional Ethics Committee
f UFPR (authorization number 240).
.3. Plant material
A. millefolium used in our experiments was collected in July
007 from the botanical garden of Universidade Paranaense (UNI-
AR, Umuarama, PR, Brazil), Umuarama (Brazil) at 430 m altitude
bove sea level (S23◦47′55–W53◦18′48). The plant was  identiﬁed
y Dr. Mariza Barion Romagnolo (Department of Botany, UNIPAR).
oucher specimens were deposited at the Herbarium of UNIPAR
nder number 2230.
.4. Preparation of the hydroethanolic extract (HEAM)Dried and powdered aerial parts of A. millefolium were extracted
ith 90% ethanol at room temperature. The solution was  concen-
rated in a vacuum rotation evaporator, ﬁltered and lyophilized to
ive the crude hydroalcoholic extract (HEAM-yielding 17.39%).ine 18 (2011) 819– 825
2.5. Isolation of the essential oil and bio-guided isolation of
artemetin
The essential oil (yielding 0.16%) was obtained from the leaves
of A. millefolium by hydrodistillation (3 h) with a clevenger type
apparatus.
The HEAM was  suspended in EtOH–H2O (1:1) and then
extracted with dichloromethane (DCM), ethyl acetate (EA), and
1-butanol (BT), successively. The solvent evaporation yielded
the fractions DCM (20%), EA (10%), and BT (50%). Since the
hypotensive activity described in this study was concentrated in
the fraction DCM, an aliquote (4.4 g) of this fraction was sub-
mitted to vacuum column chromatography in silica gel, eluted
with solvents of crescent polarity (petroleum ether, CH2Cl2,
CH2Cl2–MeOH (3:1) and pure methanol), to give four fractions
named F1 (0.06 g), F2 (1.22 g), F3 (2.68 g), and F4 (0.74 g). Our
data revealed that the activity remained in fraction F2 (DCM-2
sub-fraction). This fraction was  subjected to silica gel chromatog-
raphy column eluted with increasing amounts of ethyl acetate in
hexane, giving 20 fractions, which were subjected to TLC analy-
sis. The fraction 17 (yielded 60 mg)  was very rich in artemetin
(almost pure). It was  puriﬁed by repeated silica gel prepara-
tive TLC eluted with hexane–CH2Cl2–MeOH (2:1:0.1) to give pure
artemetin (13.8 mg), a ﬂavonoid previously reported in A. mille-
folium (Csupor-Lofﬂer et al., 2009). This compound was  identiﬁed
by 1H and 13C NMR  (200 MHz, CDCl3) under comparison with
previously reported data (Barberá et al., 1986). In our in vivo
experiments, artemetin was dissolved in a sodium bicarbon-
ate solution (0.5%), and the ﬁnal volume completed with saline
(0.9%).
2.6. Direct blood pressure measurement in anesthetized rats
Male Wistar rats were anesthetized with ketamine (100 mg/kg)
and xylazine (20 mg/kg), given by the intramuscular route, and
supplemented at 45–60 min  intervals. A polyethylene catheter was
inserted into the right femoral vein for drug administration. Imme-
diately after venous access a bolus injection of heparin (30 IU) was
administered. The animals were allowed to breath spontaneously
through a tracheostomy. The left carotid artery was  cannulated
and connected to a pressure transducer coupled to a MacLab®
recording system, and its application program (Chart, v 4.1), all
from ADI Instruments (Castle Hill, Australia), allowing the record-
ing of the mean arterial blood pressure (MAP). For stabilization of
the blood pressure after the surgical process, an interval of 15 min
was held before the injection of any drug. At the end of experi-
ments, animals were killed with an overdose of thiopental (over
40 mg/kg, i.v.).
2.7. Administration of A. millefolium extracts, fractions, and
artemetin under MAP measurement
In these experiments a single dose of HEAM (100 mg/kg, p.o.), or
vehicle (CT), were administered to the animals at 1.5, 3, 6 and 12 h
before the animals were prepared for MAP  measurement, as pre-
viously described. In another set of experiments, different animals
received a single oral dose of HEAM (30 and 300 mg/kg), butanolic
(BT-50 mg/kg), ethyl acetate (EA-10 mg/kg), dichloromethane frac-
tions (DCM-20 mg/kg), DCM-2 subfraction (3, 10 and 30 mg/kg), or
artemetin (1.5 mg/kg). Control animals (CT) received vehicle only.
All these groups were subjected for MAP  measurements at 3 h after
treatments.
The pressoric effects of artemetin after intravenous adminis-
tration were also evaluated. For this, anesthetized rats received
artemetin, at doses of 0.15, 0.35, 0.75 and 1.5 mg/kg (i.v.). An inter-
val of at least 10 min was allowed between each injection. Control
P. de Souza et al. / Phytomedicine 18 (2011) 819– 825 821
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Iig. 1. Hypotensive effect induced by A. millefolium preparations in rats. (A) The H
hange in MAP  (mm  Hg) of anesthetized rats, orally treated 3 h prior, with HEAM
ean  ± S.E.M. Statistical analyses were performed by means of one-way analysis of 
ompared to control group.
nimals received vehicle only. The dosages adopted in these exper-
ments were calculated based on the yield from the extract.
.8. Inﬂuence of artemetin in the dose-response effects of
ngiotensin I, angiotensin II, and bradykinin
All drugs used in this experiment were dissolved in saline
nd were given in a total 200 l intravenous bolus. After baseline
ssessment and stabilization of MAP  for 30 min, the rats received
ntravenous injections of angiotensin I (Ang I), or angiotensin II
Ang II), both at doses of 0.1, 1 and 3 nmol/kg, or bradykinin (BK;
0 nmol/kg). These doses were chosen accordingly to previous
tudies (Lima-Landman et al., 2007; Montenegro et al., 2009) and
ur own experience. After the measurement of the regular effects
f these drugs, different groups of animals received a single intra-
enous injection of artemetin (0.75 mg/kg), captopril (10 nmol/kg),
osartan (1 mg/kg), or saline (CT). Five minutes after these treat-
ents the injections of Angio I, Angio II, and BK were repeated, and
ompared with those effects obtained before.
.9. Angiotensin-converting enzyme (ACE) assay
The animals were orally treated, 3 h prior, with artemetin
1.5 mg/kg), captopril (20 mg/kg) or control (vehicle). Blood was
ollected into glass tubes, and serum was separated by centrifu-
ation (3000 rpm) by 15 min. Brieﬂy, serum (10 l) was  incubated
ith 490 l of assay solution containing 5 mM Hip-His-Leu in 0.4 M
odium borate buffer, pH 8.3, and 0.9 M NaCl for 15 min  at 37 ◦C.
he reaction was stopped by addition of 1.2 ml  of NaOH 0.34 N.
he product, His-Leu, was measured ﬂuorometrically (365 nm exci-
ation and 495 emission, Aminco Model J4-7461 ﬂuoromonitor,
merican Instrument Co., Silver Springs, MD)  after the addition of
00 l of o-phthaldialdehyde (20 mg/ml) in methanol, which was
ollowed 10 min  later by the addition of 200 l of HCl 3 N and cen-
rifugation at 800 × g for 5 min  at room temperature. To correct
he intrinsic ﬂuorescence of the plasma, time-zero blank samples
ere prepared by adding plasma after NaOH treatment. All mea-
urements were made in triplicate.
.10. In vitro assessment of vascular response to angiotensin I
For this experiment, we used the descending thoracic aortas
f these animals treated for blood collection (as described above).
solated aorta rings were prepared according to the standard pro-
edures previously described (Da Silva-Santos et al., 2002). Tension
as recorded via isometric force transducers (Letica Scientiﬁc
nstruments, Barcelone, Spain) coupled to a MacLab® recording was  administered by oral route at different times before MAP  measurement. (B)
“CT” refers to the control group, treated with vehicle only. The results show the
ce (ANOVA) followed by t-test subjected to Bonferroni’s correction. **p < 0.01 when
system (MacLab/8) and an application program (Chart versus 3.3),
both from ADI Instruments (Castle Hill, Australia), working on an
Apple Computer®. After one hour the preparations were exposed
to angiotensin I (1 nM–10 M)-induced vasoconstriction. The val-
ues of vasoconstriction (in grams) of control group were compared
with the results obtained in the animals that received artemetin or
captopril treatment.
2.11. Statistical analysis
Results are expressed as the mean values ± S.E.M. (standard
error of mean) of four to eight animals. The statistical evaluation
was carried out using Student’s t-test or one-way analysis of vari-
ance (ANOVA) followed by Bonferroni’s t-test. In all analysis, a p
value < 0.05 was considered as statistically signiﬁcant. Graphs were
drawn and statistical analyses were carried out using GraphPad
Prism version 5.00 for Windows (GraphPad Software, San Diego,
CA, USA).
3. Results
3.1. Reduction of blood pressure by the hydroethanolic extract
from A. millefolium (HEAM)
In control animals the basal MAP  recorded was
116.4 ± 2.5 mm Hg. The MAP  was signiﬁcantly smaller in those
animals that received HEAM (100 mg/kg, p.o.) 3 h (but not 1.5, 6 or
12 h) before the experiments, about 13 ± 1 mm Hg (Fig. 1A). The
highest dose of HEAM tested in our experiments (300 mg/kg, p.o.)
decreased the mean arterial pressure by 14 ± 3 mm Hg (Fig. 1B),
while the oral (30, 100 or 300 mg/kg) or endovenous (3, 10 or
30 mg/kg) administration of essential oil obtained from A. mille-
folium did not alter the MAP  after 3 h from each administration
(results not shown).
3.2. Effects of fractions obtained from HEAM and artemetin
isolated from A. millefolium in the mean arterial pressure of
anesthetized rats
The oral administration of DCM fraction (20 mg/kg), 3 h before
blood pressure measurement, signiﬁcantly reduced the MAP  of
anesthetized rats, when compared to the control group (treated
with vehicle only) in 11 ± 1 mm  Hg. On the other hand, nei-
ther the butanolic (BT, 50 mg/kg, p.o.), nor the ethyl acetate (EA,
10 mg/kg, p.o.) fractions caused similar blood pressure reduction
(Fig. 2A). The F2, DCM-2 sub-fraction (that was obtained from
DCM fraction), reduced the mean arterial pressure by 10 ± 1 mm  Hg
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cig. 2. Hypotensive effect induced by DCM fraction and DCM-2 sub-fraction in ra
T  and EA fractions. (B) Hypotensive effect induced by DCM-2 sub-fraction (admi
ith  vehicle only. The results show the mean ± S.E.M. Statistical analyses were perf
onferroni’s correction. **p < 0.01 when compared to control group.
hen orally administered, 3 h before blood pressure measurements
Fig. 2B). In addition, artemetin isolated from F2 (DCM-2 sub-
raction) presented a similar ability to reduce the mean arterial
ressure when orally administered 3 h before the experiments, and
aused a dose-dependent hypotensive effect when intravenously
dministered (0.15, 0.35, 0.75 and 1.5 mg/kg; i.v.), as illustrated in
ig. 3C, with reductions about 8 ± 3 mm Hg per oral route (Fig. 3B)
nd 5.6 ± 0.91 to 11.47 ± 1.5 mm Hg by intravenous administration
Fig. 3B). Artemetin (Fig. 3A) was found as the main component of
CM and DCM-2 by analysis of NMR 1H spectra of these fractions.
.3. Effects of artemetin on vascular responses to angiotensin I,
ngiotensin II and bradykinin
In order to determine if the hypotensive effect of artemetin
ould be related to any action on the renin-angiotensin sys-
em, we carried out an in vivo protocol to evaluate the activity
ig. 3. Hypotensive effect induced by artemetin isolated from A. millefolium in rats. (A) Ch
n  anesthetized rats pretreated (by oral route) with artemetin. (C) Dose-dependent hypo
he  control group, treated with vehicle only. The results show the mean ± S.E.M. Statist
ollowed by t test subjected to Bonferroni’s correction (panel C), or unpaired Student’s t-te
ompared to artemetin 0.35 mg/kg group. Change in MAP  (mm  Hg) of anesthetized rats, orally treated 3 h prior, with DCM,
ed orally 3 h before the experiment). The “CT” refers to the control group, treated
 by means of one-way analysis of variance (ANOVA) followed by t test subjected to
of angiotensin-converting enzyme (ACE). Injection of artemetin
(0.75 mg/kg) reduced the hypertensive effects of Ang I by ∼40–50%,
when compared to the control group (Fig. 4A). Similarly, the aver-
age length of the effects of Ang I was decreased in artemetin-treated
rats (Fig. 4B). The effects of artemetin on Ang I-induced hyperten-
sion were very similar to that observed in animals treated with
captopril (10 nmol/kg) (Fig. 4A and B). In addition, administration
of artemetin (as well as captopril) increased the average length
of vasodilatation induced by bradykinin (Fig. 4D), without change
the peak of vasodilatation induced by this drug (Fig. 4C). Differ-
ently than losartan, artemetin was  unable to avoid the hypertensive
effects of Ang II (Fig. 6).3.4. Artemetin induces change in plasma and vascular ECA
activity
We found signiﬁcant changes in plasma ECA activity in
rats pre-treated with artemetin and captopril (101.8 ± 12 his-
emical structure of methoxylated ﬂavonoid artemetin. (B) Change in MAP  (mm  Hg)
tensive effect of artemetin intravenously administrated in rats. The “CT” refers to
ical analyses were performed by means of one-way analysis of variance (ANOVA)
st (panel B). *p < 0.05, ***p < 0.001 when compared to control group. #p < 0.05 when
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Fig. 4. Artemetin reduces the vasoconstriction induced by angiotensin I and increases vasodilatation by bradykinin. Change in MAP  (A) and average length of the hypertensive
effect  (B) of angiotensin I in anesthetized rats, after intravenous administration of artemetin or captopril. Change in MAP  (C) and prolongation of bradykinin effects by artemetin
and  captopril administration (D). Control groups received vehicle only. The results show the mean ± S.E.M. Statistical analyses were performed by means of one-way analysis
of  variance (ANOVA) followed by t-tests subjected to Bonferroni’s correction. *p < 0.05, **p < 0.01 when compared to control group.
Fig. 5. Vascular angiotensin-converting enzyme (ACE) activity inhibition by artemetin. Rats were treated with vehicle (control), artemetin and captopril, per oral route (3 h
before). (A) ACE activity was assessed using a ﬂuorometric method with the use of Hyppuryl-His-Leu as substrate. (B) The isolated aorta rings were exposed to angiotensin
I  induced vasoconstriction. Statistical analyses were performed by means of one-way analysis of variance (ANOVA) followed by t-test subjected to Bonferroni’s correction.
*p  < 0.05, **p < 0.01 when compared to control group.
Fig. 6. Artemetin does not block angiotensin II-induced hypertension. Change in MAP  (A) and average length of the hypertensive effect (B) of angiotensin II in anesthetized
rats  after intravenous administration of artemetin or losartan. Statistical analyses were performed by means of one-way analysis of variance (ANOVA) followed by t test
subjected to Bonferroni’s correction. *p < 0.05, **p < 0.01 when compared to control group.
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eu nmol/min−1/ml−1 and 96 ± 16 his-leu nmol/min−1/ml−1) com-
ared with those found in plasma samples from rats in the control
roup (161.9 ± 7.8 his-leu nmol/min−1/ml−1) (Fig. 5A). In addition,
rtemetin caused a great reduction in vasoconstrictor response to
ng I in aorta rings, about 63–89% when compared to control group.
imilar result was  observed with captopril treatment (Fig. 5B).
. Discussion
The results of the present study did show that the extract and
emi-puriﬁed fractions (DCM and DCM-2) obtained from A. mille-
olium L. (Asteraceae), a plant popularly used against cardiovascular
iseases in several countries, including Brazil, were able to reduce
he blood pressure of rats, after oral administration. Furthermore,
he hypotensive effect of the crude extract and fractions could be
ssociated with high levels of artemetin, a methoxylated ﬂavonoid
reviously identiﬁed in A. millefolium (Csupor-Lofﬂer et al. 2009),
nd also found in other plants, such as Artemisia arborescens (Abu
arga et al., 1995), and Cordia curassavica DC (Bayeux et al., 2002).
It has been described that several ﬂavonoids and ﬂavonoid-rich
ractions present beneﬁcial effects in the cardiovascular system,
ncluding vasodilatation (e.g. Ajay et al., 2003; Ajay et al., 2007;
ong et al., 2009; Lemos et al., 1999), antioxidant (e.g. Engler
t al., 2004; Heim et al., 2002; Modak et al., 2005; Prasad et al.,
009; Wang et al., 2010) and antihypertensive activities (e.g. Cho
t al., 2007; Magos et al., 2008). Nevertheless, the cardiovascular
ffects of artemetin have never been described. Thus, this is the ﬁrst
tudy showing that oral or intravenous administration of artemetin
educes, in a dose-dependent manner, the mean arterial pressure
f rats, suggesting that this ﬂavonoid is the main responsible for
he cardiovascular effects popularly attributed to A. millefolium.
A single dose of artemetin, as low as 1.5 mg/kg, did reduce the
AP of rats in a range of ∼10 mm Hg, even when orally admin-
stered 3 h before the measurement of blood pressure. It has been
stimated that, in humans suffering from hypertension, a reduction
f 5 mm Hg in MAP  can decreases the mortality due to stroke and
oronary events by 14 and 9%, respectively (Chobanian et al., 2003;
tamler, 1991; Whelton et al., 2002), reinforcing the importance of
ur ﬁndings (Fig. 5).
Preparations obtained from A. millefolium are continuously
elf-administered as a phytomedicine. Although neither A. mille-
olium nor artemetin have been chronically administered in our
xperiments. Further to our interest, a pioneering study showing
oxicological experiments, where sub-acute oral administration of
rtemetin was evaluated in rats, indicated a very low toxicity of this
avonoid (Sertie et al., 1990).
The reduction in blood pressure disclosed in this study after
 single administration of fractions obtained from A. millefolium
uggests that this practice may  contributes in the treatment of
ypertension in humans. Importantly, we did not evaluate the
etrimental effects of this practice, and this study was  fully devel-
ped in rats. Thus, the safety and efﬁcacy of A. millefolium in humans
emain to be investigated.
Interestingly, administration of artemetin did reduce both the
verage length of effect and the peak of hypertension induced by
ngiotensin I in rats, in a way very similar to captopril, a well-
nown ACE inhibitor (Fig. 4). The vasoconstriction induced by
ngiotensin II is dependent of its ability to binding and activates
T1 subtype receptors (Ninahuaman et al., 2007). However, our
esults indicate that artemetin does not act as an antagonist of AT1
eceptors, since differently than losartan (an AT1 receptor antag-
nist), artemetin did not reduce the effects of angiotensin II in
lood pressure. In addition, the hypotension induced by bradykinin
emained for an extended period of time in those animals treated
ith either artemetin or captopril. Taken together with the reduc-ine 18 (2011) 819– 825
tion of angiotensin I-induced vasoconstriction elicited by artemetin
both in vivo and in vitro, as well as both orally and intravenously
administered, these data suggest that the hypotensive effect of this
ﬂavonoid is, at least in part, due to ACE inhibition. Our data are in
accordance to scientiﬁc literature, where several ﬂavonoids have
been reported to inhibit ACE activity (Actis-Goretta et al., 2003;
Kameda et al., 1987; Lacaille et al., 2001; Oh et al., 2004; Wagner,
1993).
Hypertension is, in most cases, a chronic condition that
almost always must be daily treated with anti-hypertensive drugs.
Although the current clinical practice guidelines states lowering
blood pressure as a priority for people suffering from hypertension
(Lonn, 2004), the efﬁciency of the pharmacological treatment is
reduced by absence of satisfactory responses, or non-adherence for
anti-hypertensive drugs regimens, that may  be related to adverse
effects or even the ﬁnancial cost of these therapies. At least to our
known, this is the ﬁrst study showing that preparations obtained
from A. millefolium, and the ﬂavonoid artemetin, are able to cause
blood pressure reduction in rats. Artemetin is not the only active
compound, but it showed activity and certainly contributes to the
antihypertensive effect of crude extract.
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